Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;97(4):E138-E140.
doi: 10.1002/ajh.26464. Epub 2022 Jan 19.

Midostaurin therapy for indolent and smoldering systemic mastocytosis: Retrospective review of Mayo Clinic experience

Faiqa Farrukh  1 , Naseema Gangat  1 , Mithun V Shah  1 , Mark R Litzow  1 , Michelle A Elliott  1 , Kebede Begna  1 , Christopher C Hook  1 , Ayalew Tefferi  1 , Animesh Pardanani  1
Affiliations
Free article

Midostaurin therapy for indolent and smoldering systemic mastocytosis: Retrospective review of Mayo Clinic experience

Faiqa Farrukh et al. Am J Hematol. 2022 Apr.
Free article
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. Gotlib J, Kluin-Nelemans HC, George TI, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374:2530-2541. doi:10.1056/NEJMoa1513098
    1. DeAngelo DJ, George TI, Linder A, et al. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia. 2018;32:470-478. doi:10.1038/leu.2017.234
    1. Hartmann K, Gotlib J, Akin C, et al. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. J Allergy Clin Immunol. 2020;146:356-366.e354. doi:10.1016/j.jaci.2020.03.044
    1. van Anrooij B, Oude Elberink JNG, Span LFR, et al. Midostaurin in patients with indolent systemic mastocytosis: an open-label phase 2 trial. J Allergy Clin Immunol. 2018;142:1006-1008.e1007. doi:10.1016/j.jaci.2018.06.003
    1. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37:435-453. doi:10.1111/j.1365-2362.2007.01807.x

LinkOut - more resources